SCHEMBL15914611

SCHEMBL15914611

CC(c1c(-c2ccc(C#N)cc2)nc2ccc(-c3ccc(Cl)cc3)cn12)N1CCCN(C)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC2A1 P11166 10/20 0.46
▸ CYP3A4 P08684 2/20 0.39
▸ MKNK1 Q9BUB5 1/20 0.39
▸ MKNK2 Q9HBH9 1/20 0.39
▸ NR1I3 Q14994 1/20 0.38
▸ SLC2A2 P11168 1/20 0.36
▸ TOP2A P11388 1/20 0.36
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ CHRM2 P08172 1/20 0.36
▸ HTR1A P08908 1/20 0.36
▸ ADRA2A P08913 1/20 0.36
▸ CHRM1 P11229 1/20 0.36
▸ DRD1 P21728 1/20 0.36
▸ TBXA2R P21731 1/20 0.36
▸ SLC6A2 P23975 1/20 0.36
▸ SLC6A4 P31645 1/20 0.36
▸ ADRA1A P35348 1/20 0.36
▸ OPRM1 P35372 1/20 0.36
▸ DRD3 P35462 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15914937 1.00 SLC2A1 (0.46) SLC2A1CYP3A4MKNK1MKNK2NR1I3
SCHEMBL15914643 0.96 SLC2A1 (0.48) SLC2A1CYP3A4MKNK1MKNK2NR1I3
SCHEMBL15914471 0.92 SLC2A1 (0.52) SLC2A1CYP3A4SLC2A2TOP2ASMN1; SMN2
SCHEMBL15914747 0.89 SLC2A1 (0.39) SLC2A1CYP3A4MKNK1MKNK2SMN1; SMN2
SCHEMBL15914574 0.89 SLC2A1 (0.39) SLC2A1CYP3A4MKNK1MKNK2SMN1; SMN2
SCHEMBL15914729 0.87 CYP3A4 (0.36) SLC2A1CYP3A4MKNK1MKNK2HTR1A
SCHEMBL15914073 0.87 MKNK1 (0.46) SLC2A1CYP3A4MKNK1MKNK2SLC6A3
SCHEMBL15914476 0.86 SLC2A1 (0.46) SLC2A1CYP3A4SLC2A2TOP2ASMN1; SMN2
SCHEMBL15914583 0.86 CYP3A4 (0.35) SLC2A1CYP3A4MKNK1MKNK2HTR1A
SCHEMBL15914869 0.85 CYP3A4 (0.35) SLC2A1CYP3A4MKNK1MKNK2HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140221354-A1 IMIDAZO [1,2-a]PYRIDINE COMPOUNDS FOR USE IN THERAPY EMBLEM TECHNOLOGY TRANSFER GMBH (DE) 2014-08-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221354-A1 IMIDAZO [1,2-a]PYRIDINE COMPOUNDS FOR USE IN THERAPY HIF1A, HIF1AN, EGLN3 SLC2A1 1235/4885CYP3A4 1281/4885MKNK1 3718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback